This protocol describes a detailed method for efficient generation of integration-free iPSCs from human adult peripheral blood cells. With the use of four oriP/EBNA-based episomal vectors to express the reprogramming factors, KLF4, MYC, BCL-XL, or OCT4 and SOX2, thousands of iPSC colonies can be obtained from 1 mL of peripheral blood.
Induced Pluripotent Stem Cells (iPSCs) hold great promise for disease modeling and regenerative therapies. We previously reported the use of Episomal Vectors (EV) to generate integration-free iPSCs from peripheral blood mononuclear cells (PB MNCs). The episomal vectors used are DNA plasmids incorporated with oriP and EBNA1 elements from the Epstein-Barr (EB) virus, which allow for replication and long-term retainment of plasmids in mammalian cells, respectively. With further optimization, thousands of iPSC colonies can be obtained from 1 mL of peripheral blood. Two critical factors for achieving high reprogramming efficiencies are: 1) the use of a 2A "self-cleavage" peptide to link OCT4 and SOX2, thus achieving equimolar expression of the two factors; 2) the use of two vectors to express MYC and KLF4 individually. Here we describe a step-by-step protocol for generating integration-free iPSCs from adult peripheral blood samples. The generated iPSCs are integration-free as residual episomal plasmids are undetectable after five passages. Although the reprogramming efficiency is comparable to that of Sendai Virus (SV) vectors, EV plasmids are considerably more economical than the commercially available SV vectors. This affordable EV reprogramming system holds potential for clinical applications in regenerative medicine and provides an approach for the direct reprogramming of PB MNCs to integration-free mesenchymal stem cells, neural stem cells, etc.
After forced expression of several transcription factors (i.e. OCT4, SOX2, MYC and KLF4), somatic cells can be reprogrammed to induced Pluripotent Stem Cells (iPSCs), which hold great promise for applications in regenerative medicine and cell replacement therapy1-3. To date, diverse methods have been developed to increase the success rate of reprogramming4-7. Viral vectors-induced reprogramming is widely used for efficient generation of iPSCs, because viral integration leads to a high-level, stable expression of the reprogramming factors. However, permanent integration of the vector DNA into the cell genome may induce insertional mutagenesis5. In addition, insufficient inactivation of reprogramming factors may disturb iPSCs differentiation8. As such, the use of iPSCs without integration of reprogramming factors is imperative, especially for use in cell therapy applications.
Episomal Vectors (EVs) are widely used in the generation of integration-free iPSCs. The most commonly used EV is a plasmid containing two elements, origin of viral replication (oriP) and EB Nuclear Antigen 1 (EBNA1), from the Epstein-Barr (EB) virus9. The oriP element promotes plasmid replication in mammalian cells, while the EBNA1 element tethers the oriP-containing plasmid DNA to the chromosomal DNA that allows for the partitioning of the episome during division of the host cell. In comparison to other integration-free approaches, including Sendai Virus (SV) and RNA transfection, EVs possess multiple advantages5,6,10. As plasmid DNA, EVs can be readily produced and modified in house, making them extremely affordable. In addition, reprogramming with EV is a less labor-intensive process since a single transfection with EVs is sufficient for iPSC generation, whereas several RNA transfections are necessary for successful reprogramming.
Dermal fibroblasts have been used in many reprogramming studies. However, skin biopsy is not only an invasive and painful process, but also time-consuming for expanding cells to sufficient quantities for reprogramming. Of greater concern, skin cells of adult donors have often been exposed to long-term UV light radiation, which may lead to mutations associated with tumors, thus limiting the applications for iPSCs derived from skin fibroblasts11,12. Recently, it has been reported that normal human skin cells accumulate somatic mutations and multiple cancer genes, including most of the key drivers of cutaneous squamous cell carcinomas, are under strong positive selection13.
In contrast to skin fibroblasts, peripheral blood (PB) cells are a preferable source of cells for reprogramming because 1) blood cells can be easily obtained through a minimally invasive process, 2) peripheral blood cells are the progeny of hematopoietic stem cells residing in bone marrow, thus protected from harmful radiation. Peripheral blood mononuclear cells (PB MNCs) can be collected in an hour from the buffy coat layer following a simple gradient centrifugation using Ficoll-Hypaque (1.077 g/mL). The obtained PB MNCs are composed of lymphocytes, monocytes and a few Hematopoietic Progenitor Cells (HPCs) 14. Although human T lymphocytes are one of the major cell types in PB, mature T cells contain rearrangements of the T cell receptor (TCR) genes and lack an intact genome thus limiting their potential for applications15,16. However, rejuvenation of T cells via iPSC generation may have potential applications in Chimeric Antigen Receptor (CAR) T-cell therapy 17-19. In comparison, HPCs have an intact genome and are readily reprogrammable. Although only 0.01 – 0.1% cells in peripheral circulation are HPCs, these cells can be expanded ex vivo in erythroid medium that favors proliferation of erythroid progenitor cells14.
In our previous study, we used the factor BCL-XL in addition to the Yamanaka factors (OCT4, SOX2, MYC and KLF4), which resulted in a 10x increase in PB reprogramming efficency20. BCL-XL, also known as BCL2L1, is a potent inhibitor of cell death, by inhibiting activation of caspases21,22. But, BCL-XL may also play an important role in maintaining pluripotency21,22. Recently, we have further optimized our EV reprogramming system by separately expressing MYC and KLF4 with two vectors, which leads to an approximately 100x increase in reprogramming efficiency23. Using this method, the reprogramming efficiency, defined by colony number divided by starting cell number at transfection, is 0.2 - 0.5% from healthy donors. As follows, we describe the detailed experimental procedure for generating integration-free iPSCs from PB.
All of the human PB samples were obtained from anonymous adult donors with no identification information available from Tianjin Blood Center with approval of the local research ethics committee.
1. Endo-free Plasmid Preparation
2. Culture Media
3. Isolation of Peripheral Blood Mononuclear Cells (PB MNCs)
4. Expansion of PB MNCs in Erythroid Medium
5. PB MNC Nucleofection and Reprogramming
6. Expansion of iPSCs
NOTE: In most cases, large numbers of iPSC colonies appear at D 8 – 10 post nucleofection. After D 14, big iPSC colonies are usually ready for picking.
7. Selection of iPSCs without Residual Episomal Plasmids
8. Flow Cytometry
9. Confocal Imaging
10. Teratoma Assay
Harvest 1 x 106 iPSCs with cell detachment solution (0.5 mM EDTA in PBS) and resuspend cells in 200 µL DMEM/F12 diluted (1:1) Matrigel.
Using this protocol, we can obtain hundreds of colonies from 1 x 105 nucleofected PB MNCs (Figures 1A and 1B). The reprogramming efficiency is approximately 0.2 – 0.5% and the colonies express pluripotency markers (Figures 1C and 1D). iPSCs generated using the described protocol are integration-free and have the ability to form teratoma composing the 3 germ layers (Figures 1E and 1F).
Figure 1: Generation of Integration-free iPSCs from Peripheral Blood Mononuclear Cells. (A): A schematic of the protocol for reprogramming peripheral blood cells. (B): AP staining in bulk (left) and a typical ESC-like iPSC colony (right) 14 d after PB MNCs nucleofection. Scale bar: 100 µm. (C): Representative FACS diagrams of iPSCs at passage 5 expressing TRA-1-60 or SSEA4. (D): Representative confocal images of iPSC colonies expressing NANOG and OCT4. Scale bar: 100 µm. (E): Representative image of the total picture and H&E staining of teratoma comprising all three germ layers. Scale bar: 100 µm. (F): Copy numbers of residual EV plasmids in iPSCs after five passages. Specific primers for EBNA1 and WPRE were used to amplify episomal vectors. GAPDH was used as a DNA loading control. UD, undetectable. The positive lane indicates a one-copy control. Please click here to view a larger version of this figure.
Acquiring blood samples from healthy donors or patients is convenient and noninvasive, making it an attractive cell source for basic research and clinical cell therapy. Here we have described a protocol for highly efficient generation of integration-free iPSCs from peripheral blood samples. This reproducible and affordable approach should benefit the iPSC field.
We have reported that there are two critical factors responsible for the highly efficient PB reprogramming30. One is equimolar expression of OCT4 and SOX2 by using a 2A linker31. To achieve this, pEV-OCT4-2A-SOX2 is used in this protocol. The other is the use of two plasmids pEV-MYC and pEV-KLF4 to express MYC and KLF4 instead of pEV-MYC-2A-KLF4 that we previously have used30. The seemingly simple change leads to an approximately 100X increase in PB reprogramming efficiencies, which is largely due to a gradual and greater increase in the MYC:KLF4 ratio during the course of the process.
Several points should be considered for achieving high-efficiency iPSC generation from PB. PB MNCs are cultured for ~1 week in erythroid medium, which promotes proliferation and expansion of erythroid progenitor cells and thus increases reprogramming efficiency20. However, for some samples, especially for blood cells from leukemia patients, cells survive poorly when cultured in erythroid medium. In this case, it would be helpful to decrease culturing time. It is also encouraged to use 1 – 2 µg pmaxGFP vector to verify the nucleofection efficiency, which should be greater than 50%. In addition, the plasmid quality is important. It is recommended to use plasmids without endotoxin contamination (i.e. using Endo-free Plasmid Maxi Kit to extract plasmids). Poor plasmid quality may lead to significant cell death and thus reduce reprogramming efficiency. We and others have shown that hypoxia promotes iPSC generation14,32. We flush the hypoxia chamber with a mixed gas composed of 92% N2, 5% CO2 and 3% O2. If normoxia is used instead, an up to 80% reduction in reprogramming efficiency may be observed. Once the reprogramming is complete, iPSCs may be cultured in a regular humidified 5% CO2 incubator. When changing medium, it is handy to leave a small amount of spent medium (i.e. 500 µL per well in a 6-well plate), and then add fresh medium. Change medium only every other day during reprogramming, as too frequent medium change may reduce iPSCs generation33.
The new protocol we have developed has achieved a high-level PB reprogramming that is comparable to the SV reprogramming system. The EV system has several obvious advantages. For one, EV is more affordable than SV. The EV system can also be further modified by including additional factors or different combinations of multiple factors, whereas the SVs vectors are a commercial product that cannot be modified by investigators. Our current protocol includes the use of MEF feeder cells and animal-derived products, which may limit the clinical applications, but can be easily removed by further protocol development34,35.
iPSCs generated with this system can be used not only for disease modeling and drug screening, but also for clinical therapy, because GMP-level EV plasmids can be easily generated and no iPSCs with considerable EV integration has been identified. In clinical applications, patient cells usually harbor a disease-inducing gene, which needs to be corrected in the iPSCs before differentiation into functional cells for therapy. A recent report showed that the EV reprogramming system can be easily integrated with the CRISPR/Cas9 system to achieve simultaneous reprogramming and genome editing after a simple nucleofection36. This is another advantage of EV over the SV system. Our unpublished data have shown that up to a 20% genome editing efficiency can be achieved when piggybacking genome editing upon EV reprogramming. It is our hope that integration of PB reprogramming with CRISP/Cas9R genome editing may have potential applications in treating multiple diseases that are otherwise incurable in the coming decades.
In summary, our improved peripheral blood cell reprogramming protocol should be useful for a wide-spectrum of investigators in basic research and clinical applications. This efficient EV reprogramming system can also be employed, after modifications, to generate integration-free Mesenchymal Stem Cells (MSCs)37, or Neural Stem Cells (NSCs)38, directly from adult peripheral blood cells without passing through an iPSC stage.
The authors have nothing to disclose.
This work was supported by the Ministry of Science and Technology of China (2015CB964902, 2013CB966902 and 2012CB966601), the National Natural Science Foundation of China (81500148, 81570164 and 81421002), the Loma Linda University School of Medicine GCAT grant (2015), and Telemedicine and Advanced Technology Research Center (W81XWH-08-1-0697).
Hematopoietic Stem Cell Expansion Medium | Sigma | S0192 | Store at 4 °C |
Human stem cell factor (SCF) | Peprotech | 300-07 | Store at -20 or -80°C |
Interleukin-3 (IL-3) | Peprotech | AF-200-03 | Store at -20 or -80°C |
Eryrthropoietin (EPO) | Peprotech | 100-64 | Store at -20 or -80°C |
Insulin growth factor-1 (IGF-1) | Peprotech | 100-11 | Store at -20 or -80°C |
Dexamethasone | Sigma | D4902 | Store at -20 or -80°C |
1-thioglycerol (MTG) | Sigma | M6145 | Store at -20 or -80°C |
DMEM/F12 medium | Gibco | 112660-012 | Store at 4 °C |
L-glutamine (100x) | Gibco | 25030-081 | Store at -20 °C |
Penicillin/Streptomycin (100x) | Gibco | 15140-122 | Store at -20 °C |
Non-essential amino acids solution (100x) | Gibco | 11140-050 | Store at 4 °C |
Fibroblast growth factor 2 (FGF2) | Peprotech | 100-18B | Store at -20 or -80°C |
ITS (100x) | Gibco | 41400-045 | Store at 4 °C |
Ascorbic acid | Sigma | 49752 | Store at -20 °C |
DMEM (high glucose) medium | Thermo | SH30243.01B | Store at 4 °C |
FBS | Hyclone | SV30087.01 | Store at -40 °C |
Ficoll | GE Healthcare, SIGMA | 17-5442-02 | Store at RT |
Trehalose | Sigma | T9531 | Store at 4 °C |
DMSO | Sigma | D2650 | Store at RT, protect from light |
Endofree Plasmid Maxi Kit(10) | Qiagen | 12362 | Store at RT |
IMDM | Gibco | 21056-023 | Store at 4 °C |
Human CD34+ Cell Nucleofection Kit | Lonza | VPA-1003 | Store at RT, nucleofection buffer and supplement buffer should be stored at 4 °C |
Sodium butyrate | Sigma | B5887 | Store at -20 or -80°C |
ROCK inhibitor Y27632 | STEMGENT | 04-0012-10 | Store at -20 °C |
Essential 8 basal medium (E8) | Gibco | A15169-01 | Store at 4 °C, the supplement should be stored at -20 or -80°C |
Matrigel | BD | 354277 | Store at -20 or -80°C |
2x EasyTaq PCR SuperMix(+dye) | TransGen Biotech | AS111 | Store at -20 °C |
Cell detachment solution | STEMGENT | 01-0006 | Store at -20 °C, Accutase as a cell detachment solution to obtain a single cell suspension |
DAPI | Sigma | D9542-1MG | Store at 4 °C or -20 °C |
Anti-nanog-AF488 | BD | 560791 | Store at 4 °C, primary antibody used for Immunofluorescence, dilute 1/100 when use |
Anti-OCT4 | abcam | ab19857 | Store at 4 °C, primary antibody used for Immunofluorescence, dilute 1/100 when use |
AF488 donkey anti-mouse IgG | Invitrogen | A21202 | Store at 4 °C, secondary antibody used for Immunofluorescence, dilute 1/500 when use |
PE anti-human TRA-1-60-R Antibody | Biolegend | 330610 | Store at 4 °C, antibody used for flow cytometry |
eFluor 570-conjugated anti-SSEA4 | eBioscience | 41-8843 | Store at 4 °C, antibody used for flow cytometry |
Isotype antibody | eBioscience | 11-4011 | Store at 4 °C, antibody used for flow cytometry |
Alkaline Phosphatase Detection Kit | SiDanSai | 1102-100 | Store at 4 °C |
Genomic DNA Extraction Kit | TIANGEN | DP304-02 | Store at RT |
Trypan Blue solution | Sigma | T8154 | Store at RT |
Flow cytometry cell analyzer | BD | LSRII | for flow cytometry analysis |
Spinning disk confocal microscope (SDC) | PerkinElmer | UltraVIEW VOX | for confocal imaging |
Nucleofection device | Lonza | Nucleofector 2b | for the nucleofection of PB MNC |
ImageQuant LAS-4010 | GE | take photo of AP staining in bulk |